As was the case with 4SP65, if H1437 and TOV21G cells were omitted from the analyses, comparisons of the dose-response metrics for the remaining six TP53 mutant cancer cell lines to the corresponding values for the other three TP53 wild-type cancer cell lines showed that the TP53-mutated cell lines were significantly more responsive (by ~1.8-fold lower concentrations of drug) than TP53 wild-type cell lines to 1LP65 treatment (Table 4). The gene discussed is TP53; the disease is cancer.